Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Simulations Plus
(NASDAQ:SLP)
Intraday
$45.67
-0.98
[-2.10%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$45.67
-0.98
[-2.10%]
Last update: 10:28AM
Get Real Time Here
Get Report
Watch
The dividend Ex-Date is tomorrow
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Simulations Plus Stock (NASDAQ:SLP)
Simulations Plus Stock (NASDAQ: SLP)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, April 05, 2024
Why Reliance Global Group Shares Are Trading Lower By Around 11%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Apr 5, 2024, 5:45AM
Thursday, April 04, 2024
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
-
Apr 4, 2024, 1:21PM
Simulations Plus Announces U.S. FDA Renews DILIsym Software Licenses For 7th Year
Benzinga Newsdesk
-
Apr 4, 2024, 8:35AM
Why Flora Growth Shares Are Trading Lower By Around 20%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Apr 4, 2024, 7:58AM
Simulations Plus shares are trading higher after the company reported better-than-expected Q2 financial results and issued guidance.
Benzinga Newsdesk
-
Apr 4, 2024, 7:14AM
Simulations Plus Posts Upbeat, Joins Levi Strauss, BlackBerry And Other Big Stocks Moving Higher In Thursday's Pre-Market Session
Avi Kapoor
-
Apr 4, 2024, 5:18AM
Levi Strauss, Conagra Brands And 3 Stocks To Watch Heading Into Thursday
Avi Kapoor
-
Apr 4, 2024, 1:53AM
Wednesday, April 03, 2024
Simulations Plus shares are trading higher after the company reported better-than-expected Q2 financial results and issued guidance.
Benzinga Newsdesk
-
Apr 3, 2024, 4:42PM
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
Apr 3, 2024, 4:31PM
CORRECTION: Simulations Plus Sees FY24 EPS $0.66-$0.68 Vs $0.66 Est.; Revenue $66M-$69M Vs $67.160M Est.
Benzinga Newsdesk
-
Apr 3, 2024, 4:30PM
Simulations Plus Q2 2024 Adj EPS $0.20 Beats $0.19 Estimate, Sales $18.300M Beat $17.283M Estimate
Benzinga Newsdesk
-
Apr 3, 2024, 4:09PM
Earnings Scheduled For April 3, 2024
Benzinga Insights
-
Apr 3, 2024, 5:36AM
Tuesday, March 05, 2024
Simulations Plus And University Of Bath Awarded FDA Grant
Benzinga Newsdesk
-
Mar 5, 2024, 8:31AM
Thursday, February 15, 2024
Simulations Plus Extends Collaboration With Translational Toxicology Division At National Institute Of Environmental Health Sciences For Rapid Safety Assessment Of Chemicals In Animals And Humans
Benzinga Newsdesk
-
Feb 15, 2024, 8:39AM
Monday, February 05, 2024
Simulations Plus Nurtures Growth and Provides Investors with Value.
Benzinga Insights
-
Feb 5, 2024, 10:05AM
Tuesday, January 23, 2024
Simulations Plus: Dividend Insights
Benzinga Insights
-
Jan 23, 2024, 9:45AM
Tuesday, January 09, 2024
Simulations Plus Embarks On Collaboration With Northeastern University And The TIM Company Through New FDA Grant
Benzinga Newsdesk
-
Jan 9, 2024, 8:41AM
Thursday, January 04, 2024
Craig-Hallum Maintains Buy on Simulations Plus, Raises Price Target to $51
Benzinga Newsdesk
-
Jan 4, 2024, 2:26PM
Wednesday, January 03, 2024
Simulations Plus: Q1 Earnings Insights
Benzinga Insights
-
Jan 3, 2024, 4:10PM
Simulations Plus Maintains FY24 EPS Guidance $0.66-$0.68 vs $0.67 Est., Revenue Guidance $66M-$69M vs $67.02M Est.
Benzinga Newsdesk
-
Jan 3, 2024, 4:08PM
Simulations Plus Q1 Adj $0.10, Inline, Sales $14.50M Beat $13.93M Estimate
Benzinga Newsdesk
-
Jan 3, 2024, 4:07PM
Earnings Scheduled For January 3, 2024
Benzinga Insights
-
Jan 3, 2024, 5:38AM
Tuesday, January 02, 2024
Earnings Preview: Simulations Plus
Benzinga Insights
-
Jan 2, 2024, 9:00AM
Monday, November 06, 2023
Stable Payouts, Increasing Performance: Simulations Plus Supports Investors with Growing Earnings
Benzinga Insights
-
Nov 6, 2023, 10:05AM
Thursday, October 26, 2023
Why Harley-Davidson Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Lisa Levin
-
Oct 26, 2023, 1:27PM
Simulations Plus shares are trading lower after the company reported worse-than-expected Q4 revenue results.
Benzinga Newsdesk
-
Oct 26, 2023, 10:07AM
Wednesday, October 25, 2023
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
Oct 25, 2023, 5:31PM
Simulations Plus Q4 Adj EPS $0.18, Inline, Sales $15.60M Miss $16.81M Estimate
Benzinga Newsdesk
-
Oct 25, 2023, 4:48PM
Earnings Scheduled For October 25, 2023
Benzinga Insights
-
Oct 25, 2023, 7:32AM
Tuesday, October 24, 2023
Simulations Plus Earnings Preview
Benzinga Insights
-
Oct 24, 2023, 2:02PM
Business Unit President at Simulations Plus Acquires Company Stock Options Worth 15,000 Shares
Benzinga Insights
-
Oct 24, 2023, 11:01AM
Simulations Plus Business Unit President Awarded $588K Worth of Stock Options
Benzinga Insights
-
Oct 24, 2023, 11:01AM
Simulations Plus Chief Executive Officer Awarded $1.96M Worth of Stock Options
Benzinga Insights
-
Oct 24, 2023, 11:01AM
Simulations Plus CFO Awarded $980K Worth of Stock Options
Benzinga Insights
-
Oct 24, 2023, 11:01AM
Tuesday, August 15, 2023
Researchers Use The Simulations Plus DILIsym Platform To Predict Safety Of Combined CBD And VPA Treatment
Happy Mohamed
-
Aug 15, 2023, 8:44AM
Tuesday, July 18, 2023
Simulations Plus Board Member Trades Company's Stock
Benzinga Insights
-
Jul 18, 2023, 11:01AM
Friday, July 07, 2023
Simulations An Attractive Vehicle For Investors Seeking Exposure To Biotech Innovation Themes, Analyst Says
Nabaparna Bhattacharya
-
Jul 7, 2023, 2:47PM
Oppenheimer Reiterates Outperform on Simulations Plus, Maintains $67 Price Target
Benzinga Newsdesk
-
Jul 7, 2023, 7:57AM
Costco, AZZ And 3 Stocks To Watch Heading Into Friday
Lisa Levin
-
Jul 7, 2023, 4:23AM
Thursday, July 06, 2023
Recap: Simulations Plus Q3 Earnings
Benzinga Insights
-
Jul 6, 2023, 4:20PM
Simulations Plus Sees FY23 EPS $0.63-$0.67 Vs $0.65 Est; Revenue $59.3M-$62.0M Vs $61.04M Est
Benzinga Newsdesk
-
Jul 6, 2023, 4:12PM
Simulations Plus Q3 EPS $0.20, Inline, Sales $16.20M Miss $16.34M Estimate
Benzinga Newsdesk
-
Jul 6, 2023, 4:07PM
Earnings Scheduled For July 6, 2023
Benzinga Insights
-
Jul 6, 2023, 4:59AM
Wednesday, July 05, 2023
Simulations Plus's Earnings: A Preview
Benzinga Insights
-
Jul 5, 2023, 10:00AM
Wednesday, June 21, 2023
Simulations Plus Is High-Growth Investment Opportunity In The Wake Of Immunetrics Acquisition: Analyst
Nabaparna Bhattacharya
-
Jun 21, 2023, 2:56PM
Oppenheimer Maintains Outperform on Simulations Plus, Raises Price Target to $67
Benzinga Newsdesk
-
Jun 21, 2023, 7:28AM
Tuesday, June 20, 2023
Simulations Plus Acquires Immunetrics For $15.5M, Expands Immunology And Oncology Drug Development Capabilities
Benzinga Newsdesk
-
Jun 20, 2023, 8:03AM
Tuesday, May 09, 2023
Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2023
Benzinga Insights
-
May 9, 2023, 11:00AM
BTIG Initiates Coverage On Simulations Plus with Buy Rating, Announces Price Target of $55
Benzinga Newsdesk
-
May 9, 2023, 6:04AM
Friday, April 28, 2023
Roblox And 3 Other Stocks Insiders Are Selling
Lisa Levin
-
Apr 28, 2023, 9:00AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch